Efficacy and safety of raltegravir in switch strategies in virologically suppressed patients: long-term data from clinical practice

2019 ◽  
Vol 74 (8) ◽  
pp. 2470-2472
Author(s):  
Arianna Emiliozzi ◽  
Arturo Ciccullo ◽  
Gianmaria Baldin ◽  
Davide Moschese ◽  
Alex Dusina ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Efficacy And Safety ◽  
Term Data

scholarly journals Efficacy and safety of long term entecavir in chronic hepatitis B treatment naïve patients in clinical practice

2014 ◽  
Vol 13 (3) ◽  
pp. 327-336 ◽  
Author(s):  
Ezequiel Ridruejo ◽  
Sebastián Marciano ◽  
Omar Galdame ◽  
María V. Reggiardo ◽  
Alberto E. Muñoz ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Clinical Practice ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Efficacy And Safety ◽  
Hepatitis B Treatment ◽  
Treatment Naïve

Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long-term data of the SIGNS study

2017 ◽  
Vol 99 (2) ◽  
pp. 169-177 ◽  
Author(s):  
Marcel Reiser ◽  
Michael Borte ◽  
Dörte Huscher ◽  
Ulrich Baumann ◽  
David Pittrow ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Term Data

scholarly journals Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice

2018 ◽  
Vol 90 (7) ◽  
pp. 70-76 ◽  
Author(s):  
V V PTUSHKIN ◽  
O Yu VINOGRADOVA ◽  
M M PANKRASHKINA ◽  
M V CHERNIKOV ◽  
E G ARSHANSKAYA ◽  
...  
Keyword(s):  
Platelet Count ◽  
Clinical Practice ◽  
Safety Data ◽  
Treatment Withdrawal ◽  
Long Term Results ◽  
Efficacy And Safety ◽  
Platelet Response ◽  
Platelet Counts ◽  
Real Clinical Practice

Objective: To analyze the long-term efficacy and safety of ATR in adult patients with primary resistant ITP in real-world clinical practice. Materials and methods.The article contains long-term results analysis of ATR application under real clinical practice conditions in 138 patients (40 men and 98 women) whose median age at the beginning of therapy was 59 (18-86) years. Two ATR medicines-romiplostim (100 patients) and eltrombopag (38 patients) were used. Results. During the first month of therapy, the median platelet count in the romiplostim group increased from 17·109 / L to 60·109 / L (9-600·109 / L), and the elethrombopag from 16.109 / L to 56.109 / L (9-400·109 / L). The minimal response (reaching platelet counts over 30·109 / L) was achieved in 92% of cases in both groups. Partial response (achievement of platelet count more than 50·109 / L) was achieved in 91 and 84% of patients in the rhombostim and eltrombopag groups, respectively. The frequency of complete response (an increase in platelet counts above 100·109 / L) was noted somewhat more often in the rhyploistim group-69% compared to 47% in the eltrombopag group (P = NS). Most patients demonstrated a long-term stable effect in the form of an increase in blood platelet count to a safe level during months and years of ATR treatment. The achievement of at least partial remission for 3 months or more was 70 and 71% in romiplostim and elthrombopag groups, respectively. Patients who started ATR- therapy are currently continuing treatment: 51% - in romiplostim group and in eltrombopag group-39%. The main reason of discontinuation the initially effective therapy were the loss of platelet response, toxicity, withdrawal from treatment (withdrawal with preservation of remission) and patients death. The tolerability of drugs with long-term admission was satisfactory. The most common AE were headache, bone pain, thrombosis, increased blood pressure and petechial hemorrhagic eruptions. The overall incidence of complications did not differ significantly between the romiplostim and eltrombopag groups -15.6 and 15.8%, respectively. Conclusion. Long-term ATR-therapy using in patients with resistant chronic ITP is an effective and largely safe treatment option.

Sign in / Sign up

Export Citation Format

Share Document